Yes, for eligible patients it creates a separate access pathway that should not be confused with a manufacturer cash offer or ordinary Part D coverage. CMS states that the demonstration began July 1, 2026 and operates outside the Part D benefit payment flow. (cms.gov)
CMS’s materials identify eligible formulations of Foundayo, Wegovy and Zepbound KwikPen; Zepbound single-dose pens and vials are not included in the listed Bridge formulations. Eligible patients have a $50 monthly copay, with detailed clinical and coverage conditions. (cms.gov)
For procurement, require the pharmacy to demonstrate:
- Distinguishing Bridge from Part D and self-pay routes.
- Handling the relevant product identifiers.
- Initiating and tracking the correct authorization process.
- Returning actionable rejection information.
- Avoiding unsupported promises of universal Medicare eligibility.
CMS provides pharmacy-specific routing instructions and prescriber materials. Use those rather than adapting an ordinary commercial-insurance workflow from memory. (cms.gov)
Keep Bridge patients separate in cost and turnaround reporting so they do not distort the self-pay comparison.
Sources cited on this page
- cms.gov · Source 1 ↗https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-part-d-plans?utm_source=openai
- cms.gov · Source 2 ↗https://www.cms.gov/files/document/glp-1-pharmacies-c.pdf?utm_source=openai